Bolder Biotechnology Inc.
Louisville, CO
- UEI
- CJ6GFX2TU3J4
- CAGE
- 1PUB8
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- NAICS codes registered in SAM.gov
- SAM.gov registration date
- Physical address
- 907 Pikes Peak Ln, Louisville, CO 80027, USA
- Website
- bolderbio.com
- Employees
- 1-10
- Estimated annual revenue
- $0-$1M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Recent federal awards
About Bolder Biotechnology Inc.
Bolder Biotechnology Inc. is a self-certified small disadvantaged business and for-profit organization that specializes in developing medical countermeasures and treatments for radiation exposure and infectious diseases. The company primarily provides research and development services to the federal government through contracts and grants focused on advanced biotechnology solutions. Bolder Biotechnology has been registered to receive federal awards since March 1, 2002, and has a consistent track record of securing funding from agencies such as the National Institute of Allergy and Infectious Diseases (NIAID) and the Department of the Army Medical Command.
In terms of federal contracts, Bolder Biotechnology has been awarded significant funding for the development of radiation medical countermeasures. A notable example is a $3,079,369 cost-plus-fixed-fee contract from NIAID for the advanced development of BBT-059, a treatment designed to mitigate radiation-associated injuries when administered up to 48 hours after exposure. This contract, awarded in July 2023, supports the company's efforts to create a safe and effective treatment as part of NIAID's broader mission to address public health needs related to radiological or nuclear incidents. Additionally, the company received a $249,876.75 Small Business Innovation Research (SBIR) Phase I purchase order from the Department of the Army Medical Command in August 2021 to evaluate BBT-059 as a medical countermeasure against hematopoietic acute radiation syndrome. These contracts demonstrate Bolder Biotechnology's expertise in developing specialized treatments for radiation exposure and its ability to secure funding from both civilian and defense agencies.
Bolder Biotechnology's federal grant awards further showcase its capabilities in biotechnology research and development. In February 2024, the company received a $591,848 Project Grant from NIAID under the Allergy and Infectious Diseases Research program. This grant supports the development of pegylated interferon gamma (PEG IFN-gh) analogues as a novel treatment to rapidly stimulate the innate immune system and improve survival from infections caused by Burkholderia pseudomallei. The research aims to create a fast-acting treatment that can provide protection within hours and be easily administered to patients, first responders, and healthcare providers in emergency outbreak situations. Another significant grant awarded in July 2021 focused on stimulating innate immunity to protect against Ebola virus infection. This project aimed to develop a long-acting human interferon gamma analog (PEG IFNG) with superior bioavailability and efficacy compared to standard interferon gamma. These grants highlight Bolder Biotechnology's commitment to advancing treatments for a range of infectious diseases and bioterrorism threats, leveraging its expertise in protein engineering and immunology.
Quick answers
What is Bolder Biotechnology Inc.'s UEI?
Bolder Biotechnology Inc.'s Unique Entity ID (UEI) in SAM.gov is CJ6GFX2TU3J4.
What is Bolder Biotechnology Inc.'s CAGE code?
Bolder Biotechnology Inc.'s CAGE code is 1PUB8.
What is Bolder Biotechnology Inc.'s primary NAICS code?
Bolder Biotechnology Inc.'s primary NAICS code is 541714 (Research and Development in Biotechnology (except Nanobiotechnology)).
Where is Bolder Biotechnology Inc. located?
Bolder Biotechnology Inc.'s physical address in SAM.gov is 907 Pikes Peak Ln, Louisville, CO 80027, USA.
Is Bolder Biotechnology Inc. registered in SAM.gov?
Yes. Bolder Biotechnology Inc.'s SAM.gov registration is active through April 10, 2027.
What is Bolder Biotechnology Inc.'s most recent federal award?
Bolder Biotechnology Inc.'s most recent federal grant award is Improving survival from burkholderia pseudomallei and other pathogenic intracellular bacteria - abstract. Burkholderia… (R43AI181293), from National Institute of Allergy and Infectious Diseases, on February 1, 2024.
On GovTribe
See Bolder Biotechnology Inc.'s full federal record
- Federal contract awards
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors